Cardiovascular Comorbidity in Patients with Chronic Obstructive Pulmonary Disease: Echocardiography Changes and Their Relation to the Level of Airflow Limitation

Daniela Buklioska-Ilievska¹, Jordan Minov², Nade Kochovska-Kamchevska³, Biljana Prgova-Veljanova¹, Natasha Petkovikj¹, Vladimir Ristovski¹, Marjan Baloski¹

¹General Hospital, “8th September”, Skopje, Republic of Macedonia; ²Institute for Occupational Health of Republic of Macedonia - WHO Collaborating Center, Skopje, Republic of Macedonia

Abstract

AIM: To compare the frequency of echocardiographic changes in patients with chronic obstructive pulmonary disease (COPD) and non-COPD controls and to assess their relation to the level of airflow limitation.

METHODS: Study population included 120 subjects divided into two groups. Group 1 included 60 patients with COPD (52 male and 8 females, aged 40 to 80 years) initially diagnosed according to the actual recommendations. Group 2 included 60 subjects in whom COPD was excluded serving as a control. The study protocol consisted of completion of a questionnaire, pulmonary evaluation (dyspnea severity assessment, baseline and post-bronchodilator spirometry, gas analyses, and chest X-ray) and two dimensional (2D) Doppler echocardiography.

RESULTS: We found significantly higher mean right ventricle end-diastolic dimension (RVEDd) in COPD patients as compared to its dimension in controls (28.0 ± 4.8 mm vs. 24.4 ± 4.3 mm; P = 0.0000). Pulmonary hypertension (PH) was more frequent in COPD patients than in controls (33.3% vs. 0%; P = 0.0004) showing a linear relationship with the severity of airflow limitation. The mean value of left ventricular ejection fraction (LVEF%) was significantly lower in COPD patients than its mean value in controls (57.4 ± 6.9% vs 64.8 ± 2.7%; P = 0.0000) with no correlation with severity of airflow limitation.

CONCLUSION: Frequency of echocardiographic changes in COPD patients was significantly higher as compared to their frequency in controls in the most cases being significantly associated with the severity of airflow limitation. Echocardiography enables early, noninvasive, and accurate diagnosis of cardiac changes in COPD patients giving time for early intervention.

Introduction

Chronic obstructive pulmonary disease (COPD) is accompanied by comorbidities which have a significant impact on its prognosis. Furthermore, cardiovascular comorbidities are considered as a major cause for hospitalization and mortality in COPD patients [1], [2], [3], [4], [5], [6]. COPD affects pulmonary blood vessels, right ventricle and left ventricle leading to right ventricular dysfunction, left ventricular dysfunction, pulmonary hypertension (PH) and cor pulmonale [7].

COPD patients have two to three-fold increased risk for hospitalisation due to cardiovascular morbidity compared to patients without COPD [8]. Also, 20-30% of all patients with chronic heart failure have COPD [9], [10]. Shortness of breath and reduced effort tolerance is present in both diseases, so cardiac failure in COPD often remains unrecognised and symptoms are attributed to COPD exacerbations. The reason is that two dimensional (2D) Doppler echocardiography as a diagnostic method for heart failure is not implemented in primary care and is not a standard diagnostic procedure for pulmonologists controlling these patients [9], [11]. Mortality from cardiovascular diseases (CVD) is about 30% and in patients with mild and moderate COPD, the most common cause of hospitalisation and mortality is cardiovascular disease. Lung Health Study showed that reduction of 10% of forced expiratory volume in one second (FEV₁) value in the patients with mild and moderate COPD increases the risk of fatal cardiovascular events up to 30% and of non-fatal coronary events up to 20% [12]. As it was mentioned...
in the Towards a Revolution in COPD Health (TORCH) study, in patients with severe COPD, CVD was less significant for morbidity and mortality whereas respiratory failure was the predominant factor [13]. Prevalence of pulmonary hypertension (PH) in COPD patients is estimated to 20-30% [4]. PH in COPD patients usually is mild to moderate with mean systolic pulmonary arterial pressure (sPAP) in the stable disease of 20-35 mmHg. Only 5-10% of patients with severe COPD have severe PH [14], [15]. As it was found in the National Emphysema Treatment Trial, 90.8% of COPD patients had sPAP higher than 20 mmHg and less than 5% had sPAP higher than 35 mmHg [16]. sPAP in COPD patients usually increases slowly, approximately 0.4-0.6 mmHg per year [17], [18].

We aimed to compare the frequency of echocardiographic changes in patients with chronic obstructive pulmonary disease (COPD) and non-COPD controls and to assess their relation to the level of airflow limitation.

Material and Methods

Study design and setting

Frequency and severity of echocardiographic changes registered by 2D Doppler echocardiography in initially diagnosed COPD patients and non-COPD controls were compared in cross-sectional analysis. The study was conducted at the General Hospital "8-th September", Skopje, in the period January – May 2018 as a continuum of our investigation of the impact of cardiovascular comorbidities on COPD [19]. The study was approved by the Ethics Committee of the Medical Faculty at University "Sts.Cyril and Methodius", Skopje (03-2237/5/21.05.2018) [19].

Study population

The study population consisted of 120 subjects divided into two groups. Group 1 included 60 patients with newly diagnosed COPD following the actual Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. Also, 60 subjects in whom COPD was excluded served as a control (Group 2). Non-COPD subjects were matched to COPD patients by sex, age, body mass index (BMI), and smoking status. Written informed consent was given by all subjects before entering the study.

Inclusion and exclusion criteria for Group 1 and Group 2 are explained in our article on carotid artery disease, and lower extremities artery disease in patients with COPD published previously [19].

Study protocol

The study workup included completion of a questionnaire, as well as pulmonary and echocardiographic evaluation.

Questionnaire

The interviewer-led questionnaire consisted of four parts, including questions on demographics, smoking history, respiratory and other symptoms in the last 12 months, as well as medical history and medication use.

- The Body Mass Index (BMI) as a measure of body fat based on height and weight that applies to adult population was calculated by BMI calculator [20].

- Study subjects were classified by their smoking status according to the World Health Organization (WHO) recommendations [21].

- Respiratory symptoms in the last 12 months, i.e. cough, phlegm, dyspnea, wheezing, and chest tightness, were documented by the European Community for Coal and Steel questionnaire (ECCS-87), and the European Community Respiratory Health Survey (ECRHS) questionnaire [22], [23].

Pulmonary evaluation

The pulmonary evaluation included: dyspnea severity assessment, pre- and post-bronchodilator spirometry, arterial gas analysis, and chest X-ray.

Assessment of the degree of dyspnea was done using the British Medical Council Dyspnea Scale [24].

Pre-bronchodilator (baseline) spirometry included measures of forced vital capacity (FVC), FEV₁, FEV₁/FVC, and maximal expiratory flow at 75%, 50%, 25%, and 25-75% of FVC (MEF₇₅, MEF₅₀, MEF₂₅, and MEF₂₅₋₇₅, respectively) by electronic spirometer Spirobank G USB Spirometer (Medical International Research, Roma, Italy) with recording the best result from three measurements the FEV₁ values of which were within 5% of each other. The results of measurements were expressed as percentages of the predicted values following the actual recommendations of the European Respiratory Society (ERS) and ATS. Post-bronchodilator spirometry was performed 20 minutes after administration of 400 μg salbutamol by metered-dose inhaler through the spacer. Fixed airflow narrowing was considered if post-bronchodilator FEV₁/FVC value remained less than 0.70. The degree of FEV₁ reversibility was expressed as % FEV₁ reversibility ([post-bronchodilator FEV₁ – pre-bronchodilator FEV₁]/pre-bronchodilator FEV₁ x 100). Significant FEV₁ improvement (a change of more than 12% and more than 200 mL) in the presence of fixed airflow limitation did not negate a diagnosis of COPD [25].
The diagnosis of COPD was established according to the actual GOLD recommendations, i.e., COPD was considered by the presence of persistent airflow limitation, i.e. a post-bronchodilator FEV1/FVC value less than 0.70, in the subjects who had dyspnea, chronic cough or sputum production, and a history of exposure to risk factors for the disease (noxious particles and gases, i.e. tobacco smoke, smoke from home cooking and heating fuels, and/or occupational dusts and chemicals). Also, based on the level of the airflow limitation, the COPD severity was classified as mild, moderate, severe, and very severe (GOLD 1, GOLD 2, GOLD 3, and GOLD 4, respectively) [26].

Values of the arterial blood gases were measured using the SIEMENS RAPIDPOINT 405 System (Siemens Healthineers, Australia).

Cardiovascular evaluation

Resting 2D Doppler Echocardiography was performed by a cardiologist using General Electric Vivid 7, according to the recommendations of the American Heart Association (AHA). Measured parameters included: left ventricular end-diastolic dimension (LVEDd), left ventricular end-systolic dimension (LVESd), left atrial dimension (LA), left ventricular ejection fraction (LVEF %) by Teicholtz, interventricular septum (IVS), right ventricular end-diastolic dimension (RVEDd), right atrial dimension (RA), estimation of left ventricular diastolic dysfunction, measurement of systolic pressure in pulmonary artery (sPAP), wall abnormalities in right ventricle, and mitral, aortic, tricuspid and pulmonary valvular evaluation. Right ventricular dilation is present when RVEDd exceeded the normal range of 0.9-2.6 cm. Right ventricular systolic dysfunction was present when it was hypokinetic. E/A, i.e. diastolic filling of the left ventricle, was classified initially based on the peak mitral flow velocity of the early rapid filling wave (E) and the peak velocity of the late filling wave caused by atrial contraction (A). In normal subjects, LV elastic recoil is vigorous because of normal myocardial relaxation. Therefore, more filling is completed during early diastolic, so LVEDd is present when E/A value is less than 1.3 (age group 45-49 years), less than 1.2 (age group 50-59 years), less than 1.0 (age group 60-69 years), and less than 0.8 (age group aged equal or more than 70 years) (30). Pulmonary hypertension was defined as a sPAP value equal or higher than 30 mmHg. According to the severity degree, PH is classified as mild (sPAP = 30-50 mmHg), moderate (sPAP = 50-70 mmHg) and severe (sPAP > 70 mmHg) [27, 28].

Statistical analysis

Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS) version 17.0 for Windows. Continuous variables were expressed as mean values with standard deviation (SD), and the nominal variables as numbers and percentages. Analyses of the data included testing the differences in prevalence, comparison of the means, and testing the association mentioned above. A P-value of less than 0.05 was considered as statistically significant.

Results

Characteristics of the study subjects were similar in both EG and CG with the exception of the mean values of spirometric parameters which were significantly lower in COPD patients than in controls.

Table 1: Characteristics of the study subjects

| Characteristic | Group 1 (n = 60) | Group 2 (n = 60) |
|----------------|------------------|------------------|
| M | 52 (86.7%) | 47 (78.3%) |
| F | 8 (13.3%) | 13 (21.8%) |
| Mean age (yrs) | 65.9 ± 7.5 | 64.3 ± 8.1 |
| E | 67.9 ± 6.1 | 65.3 ± 7.4 |
| Smoking status | | |
| Active smokers | 5 (8.3%) | 37 (61.6%) |
| Ex-smokers | 25 (41.7%) | 23 (38.3%) |
| Pack-year smoked | 66.1 ± 25.8 | 64.8 ± 21.5 |
| Mean BMI | 25.8 ± 4.9 | 25.9 ± 3.1 |
| Mean baseline values | | |
| FVC (% pred) | 78.8 ± 12.3 | 113.1 ± 19.7 |
| FEV1 (% pred) | 67.9 ± 17.9 | 59.4 ± 17.2 |
| FEV1/FVC ratio | 0.6 ± 0.07 | 0.8 ± 0.04 |

Distribution of the COPD patients by severity of the disease based on the level of airflow limitation in mild, moderate, severe, and very severe form was 6.7% (4/60 patients), 35% (21/60), 36.7% (22/60), and 21.7% (13/60), respectively.

Table 2: Echocardiographic changes in COPD patients classified by the level of airflow limitation

| Echocardiographic characteristic of all COPD patients (n = 60) | GOLD 1 | GOLD 2 | GOLD 3 | GOLD 4 |
|-------------------------------------------------------------|-------|-------|-------|-------|
| Normal findings | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Mild PH | 0 (0%) | 3 (14.3%) | 6 (27.3%) | 4 (30.8%) |
| Moderate PH | 0 (0%) | 1 (4.8%) | 1 (4.5%) | 1 (14.5%) |
| Severe PH | 0 (0%) | 1 (4.8%) | 1 (4.5%) | 1 (14.7%) |
| Mild TR | 2 (50%) | 10 (47.6%) | 12 (54.5%) | 6 (46.1%) |
| Moderate TR | 0 (0%) | 0 (0%) | 3 (13.6%) | 4 (30.8%) |
| Severe TR | 0 (0%) | 1 (4.8%) | 2 (9.1%) | 0 (0%) |
| Mild PR | 0 (0%) | 2 (9.5%) | 1 (4.5%) | 1 (7.7%) |
| Severe PR | 1 (25%) | 10 (47.6%) | 13 (59.1%) | 7 (53.9%) |
| LVESd >26mm | 0 (0%) | 14 (63.6%) | 14 (63.6%) | 7 (53.9%) |
| Mild MR | 2 (50%) | 9 (42.9%) | 10 (45.4%) | 6 (46.1%) |
| Moderate MR | 0 (0%) | 3 (14.3%) | 6 (27.3%) | 3 (23.1%) |
| Severe MR | 0 (0%) | 14 (63.6%) | 14 (63.6%) | 7 (53.9%) |
| RVESd >56mm | 0 (0%) | 3 (14.3%) | 3 (13.6%) | 0 (0%) |
| LA >40mm | 2 (50%) | 9 (42.9%) | 8 (36.4%) | 5 (38.5%) |
| LA >50mm | 1 (25%) | 3 (14.3%) | 12 (54.5%) | 3 (23.1%) |

COPD: chronic obstructive pulmonary disease; GOLD: Global Initiative for Chronic Obstructive Lung Disease; PH: pulmonary hypertension; TR: tricuspid regurgitation; PR: pulmonary regurgitation; RVEDd: right ventricular end-diastolic dimension; RA: right atrial; MR: mitral regurgitation; RS: mitral stenosis; IVS: interventricular septum; LVEDd: left ventricular end-diastolic dimension; LA: left atrial; LV: left ventricle.
Registered echocardiographic changes in the subjects of Group 1 classified according to the severity of airflow limitation are presented in Table 2. The most frequent abnormality of the right heart was increased RVEDd, whereas dilated left atrium and left ventricular hypertrophy were the most frequent left heart abnormalities. Also, TR was the most frequent valvular abnormality.

Comparison of echocardiographic findings indicated a significant difference between right heart parameters in the Group 1 as compared to their values in the Group 2. Also, except interventricular septum, there was a significant difference between the two groups (Table 3).

Table 3: Comparison of certain echocardiographic parameters in the two groups

| Echocardiographic parameter | Group 1 (n = 60) | Group 2 (n = 60) | P value |
|-----------------------------|------------------|------------------|---------|
| LA (19.0-40.0 mm)           | 39.0 ± 5.3       | 36.4 ± 3.5       | 0.0019  |
| LV ≤ <35 mm                 | 33.6 ± 6.4       | 30.7 ± 2.4       | 0.0013  |
| RVEDd (7.5-35 mm)           | 28.0 ± 4.8       | 24.4 ± 4.3       | 0.0000  |
| LVEDd (35.0-56.0 mm)        | 50.0 ± 5.8       | 46.2 ± 4.1       | 0.0000  |
| LV (7.0-12 mm)              | 11.1 ± 1.9       | 11.4 ± 1.2       | 0.1032  |
| LVEF%                       | 57.4 ± 6.9       | 64.8 ± 2.7       | 0.0000  |

LA: left atrial dimension; LV: left ventricular systolic dimension; RVEDd: right ventricular end-diastolic dimension; LVEDd: left ventricular end-diastolic dimension; IVS: interventricular septum; LVEF%: left ventricle ejection fraction.

As it is mentioned above, the mean value of the LVEF% in non-COPD controls was significantly higher compared to its value in COPD patients but there was no correlation with COPD severity (Table 4).

Table 4: LVEF% value about COPD severity

| COPD severity | LVEF% value |
|---------------|-------------|
| GOLD 1        | 61.3%       |
| GOLD 2        | 56.1%       |
| GOLD 3        | 57.0%       |
| GOLD 4        | 55.6%       |

*COPD: chronic obstructive pulmonary disease; LVEF%: left ventricle ejection fraction; GOLD: Global Initiative for Chronic Obstructive Lung Disease.

Frequency of PH was significantly higher in COPD patients compared to its frequency in non-COPD controls (33.3% vs. 0%; \( P = 0.0004 \)). Frequency of PH proportionally increased with FEV1 decline (Table 5).

Table 5: Frequency of PH about the level of airflow limitation

| COPD severity | Frequency of PH |
|---------------|-----------------|
| GOLD 1        | 0%              |
| GOLD 2        | 23.8%           |
| GOLD 3        | 41.0%           |
| GOLD 4        | 46.1%           |

*COPD: chronic obstructive pulmonary disease; PH: pulmonary hypertension; GOLD: Global Initiative for Chronic Obstructive Lung Disease.

Discussion

Comorbidities such as cardiac disease, peripheral vascular disease, hypertension, metabolic syndrome, diabetes mellitus, osteoporosis, and psychological disorders are commonly presented in patients with COPD with great variability in reported prevalence. Besides, cardiovascular comorbidities are considered as an important cause of mortality in COPD patients [5, 6].

The present study aimed to compare the frequency of echocardiographic changes registered by resting 2D transthoracic Doppler echocardiography in COPD patients and non-COPD controls and to assess their relation to the level of airflow limitation. We performed a cross-sectional study including 120 subjects divided into two groups. The first group included 60 initially diagnosed with COPD, whereas the second group included an equal number of subjects in whom COPD was excluded complementary by their demographic characteristics to the patients with COPD. Airflow limitation in more than half of the newly diagnosed COPD patients was assessed as severe or very severe indicating delayed recognising of the disease and late-onset of adequate treatment.

Resting 2D Doppler echocardiography was done by the same cardiologist and valvular anatomy and function, left, and right ventricle size and cardiac function were assessed.

Values of the RV parameters were significantly higher in COPD patients. There was a high prevalence of PH, right atrial enlargement, RV systolic dysfunction and tricuspid regurgitation in COPD patients, and their severity increased with COPD severity. Cor pulmonale was found in 16.7% of our COPD patients which correlates with 17.5% in Gupta et al., a study [29].

TR peak gradient as a marker for indirect evidence of PH was studied in all patients. TR in the present study was found in 44.4% of the COPD patients, that is less than its frequency in the studies performed by Higham et al., (77%) and by Kassim et al., (70%) [30, 31]. The difference can be explained by several factors like the type of equipment used, the experience of the operator, the quality of the image obtained or the body habitus. Impairment of RV function and alteration of pulmonary blood vessels complicate the clinical course of COPD and correlates inversely with the survival of these patients [7].

LV systolic function was significantly higher in non-COPD controls as compared to the COPD patients. Frequency of the LV systolic dysfunction was 5.5% in the COPD patients, that was similar to its frequency reported in the Gupta study (7.5%). Abnormal LV performance in the patients with COPD may be due to hypoxemia, acidosis, concurrent coronary artery disease, and ventricular interdependence as the RV and LV share a common septum [29].

Two major factors implicated in the mortality of COPD are the severity of PH and the development of cor pulmonale. Cor pulmonale reduces the survival...
of up to 30% [32]. Although the true prevalence of PH in COPD is still unknown, an elevation of pulmonary arterial pressure is reported in 20-90% of patients when measured by right heart catheterisation [29]. The level of PH has a prognostic value for COPD patients that is demonstrated in several studies. In one of them, the 5-year survival rates were 50% in patients with mild PH (20-30 mmHg), 30% in those with moderate to severe PH (30-50 mmHg), and 0% in the small group of patients with severe PH (> 50 mmHg) [30]. As a conclusion, the high level of PH is associated with poor prognosis in COPD patients [7].

PH was not detected in any subject from Group 2, whereas its frequency among COPD patients was 33%. PH frequency reported in the studies conducted by Kassim et al., and Rabab et al., was 36% and 55.6%, respectively [31], [32]. Distribution of PH in patients with moderate, severe, and very severe COPD in the present study was 23.8%, 41%, and 46.1%, respectively. Increased PH prevalence following increasing level of airflow limitation is also reported in the study conducted by Gupta & Mann and Rabab i.e. the reported prevalence of PH in patients with mild, moderate, severe, and very severe COPD was 16.7%, 54.5%, 60.0% and 83.3%, respectively [29], [33].

The findings of this study are subjects of at least three limitations. Firstly, the relatively small size of the study groups may have implications on data obtained and its interpretation. Secondly, the irregular distribution of the patients with COPD by the level of airflow limitation may also impact data obtained and its interpretation. Besides, the distribution of the study subjects by sex is also unequal. On the other side, the strength of the study is echocardiographic assessment in the initially diagnosed COPD patients.

In conclusion, in a cross-sectional study on the frequency of echocardiographic changes in newly diagnosed COPD patients and their relation to the level of disease severity we found a significantly higher prevalence of echocardiographic changes in COPD patients than in non-COPD controls which were significantly related to the level of airflow limitation. Our findings indicated that echocardiographic assessment should be a constitutive part of a periodic screening of all patients with COPD to implement a combined therapeutic strategy which should reduce morbidity and mortality in these patients.

References

1. Sabit R, Bolton C. Sub-clinical left and right ventricular dysfunction in patients with COPD. Respir Med. 2010; 104(8):1171-1178. https://doi.org/10.1016/j.rmrd.2010.01.020 PMid:2085285

2. Chatilla WM, Tomashow BM, Minai OA, et al. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 8:549-556.

3. Lucas-Ramos P, Izquierdo-Alonso J, Rodriguez-Gonzalez J, et al. Chronic obstructive pulmonary disease as a cardiovascular risk factor. Results of a case-control study (CONSISTE study). Int J COPD. 2012; 7:679-686. https://doi.org/10.2147/IJCP.S36222 PMid:23055717 PMCid:PMC3468057

4. Jeremy A, Kadiev S, Criner G, et al. Cardiac disease in Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc 2008; 5(4):543-548. https://doi.org/10.1513/pats.200708-142ET PMid:18453369 PMCid:PMC2645333

5. Hunninghake D. Cardiovascular Disease in Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc. 2005; 2:44-49. https://doi.org/10.1513/pats.200410-050SF PMid:16113468

6. Finkelstein J, Cha E, Scharf S. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Int J COPD. 2009; 4:337-349. https://doi.org/10.2147/SCCOPD.S6400 PMid:19802349 PMCid:PMC2754086

7. Hirachan A, Maskey A, Shah R, et al. Echocardiographic right heart study in patients with chronic obstructive pulmonary disease. Nepalese Heart Journal. 2017; 14(2), 9-12. https://doi.org/10.3126/nhj.v14i2.18496

8. Don D, Sin, MD. Is COPD Really a Cardiovascular Disease? Chest. 2009;136(2):329-330. https://doi.org/10.1378/chest.09-0808 PMid:19666751

9. Le Jemtel TH, Padelleli M, Jelic S. Diagnostic and Therapeutic Challenges in Patients With Coexistent Chronic Obstructive Pulmonary Disease and Chronic Heart Failure. J Am Coll Cardiol. 2007; 49:171-180. https://doi.org/10.1016/j.jacc.2006.08.046 PMid:17222727

10. Hanuy Ni, Deirdre J, Nauman R, Hershberger E. Managed Care and Outcomes of Hospitalization Among Elderly Patients With Congestive Heart Failure. Arch Intern Med. 1998; 158:1221-1236. https://doi.org/10.1001/archinte.158.11.1231 PMid:9625402

11. Rutten F, Cramer M, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J. 2005; 26:1887-1894. https://doi.org/10.1093/eurheartj/ehi291 PMid:15860516

12. Alfonсинен NR, Connett JE, Enright PL, Manfreda J. Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care. 2002; 166(3):333-339. https://doi.org/10.1164/rccm.200112-21003R PMid:12153966

13. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in COPD. NEJM. 2007; 357:755-789. https://doi.org/10.1056/NEJMoa063070 PMid:17314337

14. Ashitani J-I, Muake H, Arimura Y, Matsakura S. Elevated plasma procoagulant and fibrinolytic markers in patients with chronic obstructive pulmonary disease. Intern Med. 2002; 41(3):181-185. https://doi.org/10.2169/internalmedicine.41.181 PMid:11929177

15. Pinto-Plata VM, Mülleroova H, Tosos JF, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax. 2006; 61:23-28. https://doi.org/10.1136/thx.2005.042200 PMid:16143583 PMCid:PMC2080714

16. Chaouat A, Bugnet AS, Kadaoui N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005; 172(2):189-94. https://doi.org/10.1164/rccm.200401-198OC PMid:15831842

17. Croxton J, Sterling C, Long-term Oxygen Treatment in Chronic Obstructive Pulmonary Disease: Recommendations for Future Research. 2006; 174:373-378. https://doi.org/10.1183/09064812.0580716PMid:16614349 PMCid:PMC2648117

18. Kessler R, Faller M, Weitenblum E, et al. Natural History of Pulmonary Hypertension in a Series of 131 Patients with Chronic Obstructive Lung Disease. Am J Respir Crit Care Med. 2001; 164(2):219-224. https://doi.org/10.1164/ajrccm.164.2.2006129 PMid:11463591

19. Buklioska-Ilievska D, Minov J, Kocovska-Kamcevska N, et al.
Carotid artery disease and lower extremities artery disease in patients with chronic obstructive pulmonary disease. Open Access Maced J Med Sci. 2019; 7(13):2102-7. https://doi.org/10.3889/oamjms.2019.576 PMid:31456833 PMCID:PMC668108

20. Calculate your Body Mass Index, 2018. Available at: https://www.nhlbi.nih.gov (Accessed 08.12.2018).

21. World Health Organization. Guidelines for controlling and monitoring the tobacco epidemic. Geneva: WHO, 1998.

22. Minette A. Questionnaire of the European Community for Coal and Steel (ECSC) on respiratory symptoms. 1967 - updating of the 1962 and 1967 questionnaires for studying chronic bronchitis and emphysema. Eur Respir J. 1989; 2:165-177.

23. European Community Respiratory Health Survey. Variations in the prevalence of respiratory symptoms, self-reported asthma attacks, and use of asthma medication in the European Respiratory Health Survey (ECRHS). Eur Respir J. 1996; 9:687-695. https://doi.org/10.1183/09031936.96.09040687 PMid:8729322

24. Fletcher CM. Standardised questionnaire on respiratory symptoms: a statement prepared and approved by the MRC Committee on the Aetiology of Chronic Bronchitis (MRC breathlessness score). BMJ 1960; 2:1662.

25. Miller MP, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005; 26:319-338. https://doi.org/10.1183/09031936.05.00034805 PMid:16055882

26. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Executive Summary: Global Strategy for Diagnosis, Management, and Prevention of COPD, 2018. Available at: www.goldcopd.org (Accessed 08.12.2018).

27. Rudinski LG, LAI WW. Guideline for the Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of Echocardiography Endorsed by The European Association of Echocardiography. J Am Soc Echocardiogr. 2010; 23:685-713. https://doi.org/10.1016/j.echo.2010.05.010 PMid:20620859

28. Mahmoud MM, Shalan IM, Kawshe H, Azeem H. Assessment of left ventricular function in chronic obstructive pulmonary disease. Echocardiographic study. AAMJ. 2015; 13(2):1-9.

29. Gupta NK, Agrawal RK, Srivastav AB, Ved ML. Echocardiographic evaluation of heart in chronic obstructive pulmonary disease patient and its co-relation with the severity of disease. Lung India. 2011; 28(2):101-105. https://doi.org/10.4103/0970-2113.80321 PMid:21712919 PMCID:PMC3109831

30. Higham M, Dawson D, Joshi J et al. Utility of echocardiography in assessment of pulmonary hypertension secondary to COPD. Eur Respir J. 2001; 17:350-355. https://doi.org/10.1183/09031936.01.17303500 PMid:11405510

31. Kassim M, Muataz H, Ammar I. The relation of echocardiographic findings to pulmonary function tests in patients with chronic obstructive pulmonary disease. J Fac Med. 2009; 51(1):17-22.

32. Jatav VS, Meena SR, Jelia S, et al. Echocardiographic findings in chronic obstructive pulmonary disease and correlation of right ventricular dysfunction with disease severity. Int J Adv Med. 2017; 4:476-480. https://doi.org/10.18203/2349-3933.ijam20171045

33. Rabab A. El Wahsh, Mahmoud KA, Rehab IY. Evaluation of left ventricular function in patients with chronic obstructive pulmonary disease with or without pulmonary hypertension. Egyptian Journal of Chest Diseases and Tuberculosis. 2013; 62:575-582. https://doi.org/10.1016/j.ejcdt.2013.08.004